MEKanistic Therapeutics, a biotechnology company developing first-in-class precision medicines designed to overcome cancer resistance mechanisms, today announced that the U.S. Food and Drug ...

Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have ...

Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has ...

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall ...

The FDA approved the aldosterone synthase inhibitor Baxfendy (baxdrostat) for adults with inadequately controlled hypertension.

Your pathology report includes vital information about your brain tumor that can guide treatment. Get to know how to interpret common terms.

BARCELONA, Spain—Two in five patients with heart failure (HF) have high inflammatory risk, with a similar prevalence across ...

EMERALD-3: Phase III trial of IMFINZI ® (durvalumab) in combination with IMJUDO ® (tremelimumab-actl), with or without lenvatinib, and transarterial chemoembolization (TACE) in patients with ...

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Highlighted research being presented at the 2026 ASCO Annual Meeting includes breast, colorectal, lung, endometrial and renal ...

HealthInvest in Sydney on June 3, 2026, will showcase five emerging ASX-listed healthcare companies to investors. ... Read More The post Scott Power: ASX healthcare growth stories to step into ...